The purpose of PREVENTABLE is to learn if taking a statin could help older adults live well for longer by preventing dementia, disability, or heart disease.
   
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. This study seeks to assess the benefit of statins (Atorvastatin) for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
   

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed).

The purpose of this study is to investigate differences in iron in the brains of subjects with and without beta-amyloid deposition. Iron is an essential mineral in your body, and beta-amyloid is a protein associated with Alzheimer’s disease. Studies suggest that excess iron in the brain may be involved in processes that lead to Alzheimer's disease.

We have developed and validated a non-invasive method to estimate the clearance of cerebrospinal fluid (CSF) from the brain. This study tests the hypothesis that reduced CSF clearance is predictive of a) future amyloid lesions, b) brain atrophy, and c) cognitive decline in healthy elderly adults or those with Mild Cognitive Impairment (MCI). 

 Measuring brain CSF clearance with novel, experimental imaging techniques may advance the understanding of Alzheimer’s disease (AD) progression at its earliest stages. 

This is a clinical trial for adults with cancer, which has continued to grow despite the treatments already received, because the standard drugs used to treat the disease are no longer working, because the tumor cells are resistant to available treatments, or subjects are not a candidate for or intolerant of other available treatments. The subjects with solid tumors and lymphoma are eligible for this trial.
   

The purpose of this study is to assess the efficacy of this combination of drugs in light chain (AL) amyloidosis which has relapsed or become refractory to other treatments. Amyloidosis is a rare disease that is caused by a substance called amyloid. Amyloid is an abnormal protein produced by plasma cells in the bone marrow which cannot be broken down by the body and so accumulate over time in various organs. Amyloidosis can affect different organs in different people. The most commonly affected organs are the heart, kidney, liver, spleen, nervous system, and digestive tract.

We are looking for people to participate in a Weill Cornell research study using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) to better understand brain processes that may make Traumatic Brain Injury (TBI) a risk factor for later development of Alzheimer’s Disease or Chronic Traumatic Encephalopathy (CTE).

Research study participation lasts up to two years and involves:

This research study is being done because there is a need for systemic therapies for moderately severe plaque-type psoriasis that are both effective and have minimal side effects.

The primary goal of this study is to assess whether using recent advances in technology to treat high intermediate risk and high-risk prostate cancer (HrPCa) can improve clinical outcomes, measured as recurrence-free survival at 2 years after treatment.

The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side effects. Following selection of the proper dose for each treatment regimen, the purpose of the phase II portion of the study is to test if the regimen of 225Ac-J591 leads to treatment response.